Format

Send to

Choose Destination
Kidney Int. 2015 Mar;87(3):502-28. doi: 10.1038/ki.2014.425. Epub 2015 Feb 4.

Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference.

Author information

1
Division of Nephrology, Klinikum Coburg GmbH, Coburg, Germany.
2
1] Department of Renal Medicine, Westmead Hospital, Sydney, New South Wales, Australia [2] Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
3
Department of Nephrology, University Hospitals Leuven, Leuven, Belgium.
4
1] Division of Preventive Medicine, Department of Family and Preventive Medicine, University of California, San Diego, California, USA [2] Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California, USA [3] Division of Nephrology, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
5
Women's College Research Institute, Toronto, Ontario, Canada.
6
INSERM U1059, Faculté de Médecine, Saint-Etienne, France.
7
Nephrology Unit, Great Ormond Street Hospital for Children, London, UK.
8
Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
9
1] Department of Medicine, University of Alberta, Edmonton, Canada [2] Department of Public Health Sciences, University of Alberta, Edmonton, Canada.
10
Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
11
University College London, London, UK.
12
Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Abstract

A new definition and classification of chronic kidney disease-mineral and bone disorder (CKD-MBD) was proposed in 2005 and it was later followed by a guideline publication on this topic from Kidney Disease: Improving Global Outcomes (KDIGO) in 2009. This work recognized that CKD-MBD is a syndrome of bone abnormalities, laboratory abnormalities, and vascular calcification linked to fractures, cardiovascular disease, and mortality. Because of limited data at the time of the original guideline systematic review, many of the recommendations were cautiously vague. KDIGO convened a Controversies Conference in October 2013 to review the CKD-MBD literature published since the 2009 guideline. Specifically, the objective of this conference was to determine whether sufficient new data had emerged to support a reassessment of the CKD-MBD guideline and if so to determine the scope of these potential revisions. This report summarizes the results of these proceedings, highlighting important new studies conducted in the interval since the original KDIGO CKD-MBD guideline.

PMID:
25651364
DOI:
10.1038/ki.2014.425
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center